Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Grzegorz Terszowski"'
Autor:
Charlotte Hagman, Gaetan Chasseigne, Robert Nelson, Florian Anlauff, Mark Kagan, Allison B. Goldfine, Grzegorz Terszowski, Maria Jadhav
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The clinical immunogenicity assessment for complex multidomain biological drugs is challenging due to multiple factors that must be taken into consideration. Here, we describe a strategy to overcome multiple bioanalytical challenges in order to asses
Externí odkaz:
https://doaj.org/article/7b5a650d46c844bcaf6b7b4b75ba816c
Autor:
Axel Ducret, Chloé Ackaert, Juliana Bessa, Campbell Bunce, Timothy Hickling, Vibha Jawa, Mark A. Kroenke, Kasper Lamberth, Anaïs Manin, Hweixian L. Penny, Noel Smith, Grzegorz Terszowski, Sophie Tourdot, Sebastian Spindeldreher
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
A major impediment to successful use of therapeutic protein drugs is their ability to induce anti-drug antibodies (ADA) that can alter treatment efficacy and safety in a significant number of patients. To this aim, in silico, in vitro, and in vivo to
Externí odkaz:
https://doaj.org/article/f1b08d7387d549058b5c20457db22f6b
Publikováno v:
Swiss Medical Weekly, Vol 142, Iss 4142 (2012)
Transplantation immunology has traditionally focused on adaptive, i.e., T- and B-cell reactions. More recently, natural killer (NK) cells were also recognised as playing an important role after transplantation of solid organs and haematopoietic stem
Externí odkaz:
https://doaj.org/article/9e39bf72fb5447aeb2d310aab2cb730c
Autor:
Alfred Zippelius, Michael von Bergwelt-Baildon, Daniel E. Speiser, Stephan Dirnhofer, Giulio Spagnoli, Hans-Michael Kvasnicka, Max Schlaak, Viola A. Heinzelmann-Schwarz, Didier Lardinois, Grzegorz Terszowski, Spasenija Savic, Jens Schreiner, Sebastian Theurich, Kea Martin, Philipp Müller
PDF file - 97K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31695c9c481c2b5589caf74c4d01a02b
https://doi.org/10.1158/2326-6066.22537264.v1
https://doi.org/10.1158/2326-6066.22537264.v1
Autor:
Alfred Zippelius, Michael von Bergwelt-Baildon, Daniel E. Speiser, Stephan Dirnhofer, Giulio Spagnoli, Hans-Michael Kvasnicka, Max Schlaak, Viola A. Heinzelmann-Schwarz, Didier Lardinois, Grzegorz Terszowski, Spasenija Savic, Jens Schreiner, Sebastian Theurich, Kea Martin, Philipp Müller
PDF file - 2651K, Supp. Fig. 1. Dolastatins induce phenotypic DC maturation in vitro. Supp. Fig. 2. Dolastatins induce phenotypic and functional maturation of BM-DCs in vitro. Supp. Fig. 3. Immuno-stimulatory effect of dolastatin 10 is independent of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27fba704c2975dd557cb27ba32be221a
https://doi.org/10.1158/2326-6066.22537267.v1
https://doi.org/10.1158/2326-6066.22537267.v1
Autor:
Alfred Zippelius, Michael von Bergwelt-Baildon, Daniel E. Speiser, Stephan Dirnhofer, Giulio Spagnoli, Hans-Michael Kvasnicka, Max Schlaak, Viola A. Heinzelmann-Schwarz, Didier Lardinois, Grzegorz Terszowski, Spasenija Savic, Jens Schreiner, Sebastian Theurich, Kea Martin, Philipp Müller
Antibody–drug conjugates (ADC) are emerging as powerful treatment strategies with outstanding target-specificity and high therapeutic activity in patients with cancer. Brentuximab vedotin represents a first-in-class ADC directed against CD30+ malig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ced706dfc576c5b89a568e263ac21ec
https://doi.org/10.1158/2326-6066.c.6548374.v1
https://doi.org/10.1158/2326-6066.c.6548374.v1
Autor:
Axel Ducret, Chloé Ackaert, Juliana Bessa, Campbell Bunce, Timothy Hickling, Vibha Jawa, Mark A. Kroenke, Kasper Lamberth, Anaïs Manin, Hweixian L. Penny, Noel Smith, Grzegorz Terszowski, Sophie Tourdot, Sebastian Spindeldreher
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
mAbs
article-version (VoR) Version of Record
mAbs
article-version (VoR) Version of Record
A major impediment to successful use of therapeutic protein drugs is their ability to induce anti-drug antibodies (ADA) that can alter treatment efficacy and safety in a significant number of patients. To this aim, in silico, in vitro, and in vivo to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::895f474677dd9ef988de598077b81822
https://doi.org/10.1080/19420862.2021.1993522
https://doi.org/10.1080/19420862.2021.1993522
Autor:
Grzegorz Terszowski, Asensio Gonzalez, Andreas Buser, Hojjatollah Nozad Charoudeh, Laurent Schmied, Karin Schmitter, Laura Infanti, Martin Stern, Karol Czaja
Natural killer (NK) cells require interaction of inhibitory surface receptors with human leukocyte antigen (HLA) ligands during development to acquire functional competence in a process termed “licensing.” The quantity of HLA required for this pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8cffece0d19ff91ccf081d34f2688b2
http://doc.rero.ch/record/313221/files/251_2012_Article_633.pdf
http://doc.rero.ch/record/313221/files/251_2012_Article_633.pdf
Autor:
Laurent, Schmied, Grzegorz, Terszowski, Asensio, Gonzalez, Karin, Schmitter, Hans H, Hirsch, Christian, Garzoni, Christian, van Delden, Katia, Boggian, Nicolas J, Mueller, Christoph, Berger, Jean, Villard, Oriol, Manuel, Pascal, Meylan, Christoph, Hess, Martin, Stern, Patrick, Yerly
Publikováno v:
TRANSPLANTATION
Transplantation, Vol. 99, No 12 (2015) pp. 2651-5
Transplantation, Vol. 99, No 12 (2015) pp. 2651-5
BACKGROUND: Natural killer cell function is regulated by inhibitory and activating killer cell immunoglobulin-like receptors (KIR). Previous studies have documented associations of KIR genotype with the risk of cytomegalovirus (CMV) replication after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ac4beddc08cd680935400f99cb52029
Autor:
A.-S. Borer, Asensio Gonzalez, Laurent Schmied, Karol Czaja, Martin Stern, Grzegorz Terszowski
Publikováno v:
Genes & Immunity. 15:33-37
Analysis of killer cell immunoglobulin-like receptor (KIR) expression has been notoriously difficult because of the cross-reactivity of available antibodies, in particular between activating and inhibitory isoforms. We undertook a comprehensive study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd5987ab2209133b8f0e89854b72ea25
https://doi.org/10.1038/gene.2013.58
https://doi.org/10.1038/gene.2013.58